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Aims
Despite available literature and results from RCT the
question of whether Transcatheter Aortic Valve Repla-
cement (TAVI) is cost-effective, and for whom, persists
in the UK. This paper investigates how evidence from
published literature, RTC and registry data can be
employed and best synthesised to determine the cost
effectiveness of TAVI and establish for whom is TAVI
most suitable.
Methods
A decision analytical model, incorporating a short–term
decision tree and long-term Markov model were con-
structed. The use of Monte Carlo simulation and Value
of Information analysis enables both the cost-effective-
ness of TAVI to be estimated, based on the existing
information, and the value of, and requirements for,
further evidence collection to be determined. The model
allows for the heterogeneous patient population by con-
sidering different three patient risk cohorts (low, med-
ium and high). Initially the model was populated using
the best available literature; then updated when RCT
results became available. However, the trial data did not
fully reflect UK practice as such the model was updated
with UK Registry data. Probabilistic analysis is underta-
ken at each stage and results are presented for the cost-
effectiveness and the value of undertaking further
research.
Results
The initial model results revealed that TAVI is cost-
effective for inoperable patients only compared to medi-
cal-management with an ICER of £22,603. The EVPI
per high risk patient ranges from £462 to £1,277. When
the results from the PARTNER trial were incorporated
into the model, TAVI remained cost-effective for these
patients compared to medical-management, ICER
£25,875. The EVPI using the PARTNER evidence ranged
from £69 to £1,170 per patient. At each of these stages,
there is potential value in undertaking further research
in this patient sub-group within the UK.
Conclusions
This paper reveals that a flexible model accommodating
an evolving evidence base is a necessity when dealing
with novel technologies for which data is scarce, such as
TAVI. While the US RCT evolves the database, the suit-
a b i l i t yo ft h i sd a t ai sq u e s t i o n a b l ef o raU Kc o s t - e f f e c -
tiveness model. Similarly the suitability of the UK TAVI
registry is also undefined as it is not randomised. This
paper examines how best to synthesise and incorporate
these data into a decision analytical model to reveal for
whom TAVI is cost-effective in the UK.
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